Truist analyst David MacDonald raised the firm’s price target on Pediatrix Medical (MD) to $24 from $17 and keeps a Hold rating on the shares. The firm is updating its model to reflect the company’s Q3 earnings beat and guidance raise, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Medical price target raised to $23 from $16.50 at UBS
- Pediatrix Medical Group: Strong Financial Performance and Strategic Improvements Justify Buy Rating
- Pediatrix Medical reports Q3 adjusted EPS 67c, consensus 47c
- Pediatrix Medical raises FY25 adjusted EBITDA view to $270M-$290M
- MD Earnings this Week: How Will it Perform?